{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:11:24Z","timestamp":1790784684610,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11523-025-01174-0","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:37:57Z","timestamp":1758037077000},"page":"833-845","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed\/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study"],"prefix":"10.1007","volume":"20","author":[{"given":"Patrick","family":"Hanafin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0074-1938","authenticated-orcid":false,"given":"Yu Liu","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2691-9392","authenticated-orcid":false,"given":"Theodoros","family":"Papathanasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Fulci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Sule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon E","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Ferron-Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"issue":"10","key":"1174_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","volume":"20","author":"R Montes de Oca","year":"2021","unstructured":"Montes de Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, et al. Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20(10):1941\u201355. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0035.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"1174_CR2","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.15.77","volume":"7","author":"YT Tai","year":"2015","unstructured":"Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7(11):1187\u201399. https:\/\/doi.org\/10.2217\/imt.15.77.","journal-title":"Immunotherapy"},{"issue":"10","key":"1174_CR3","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801\u201312. https:\/\/doi.org\/10.1016\/S2352-3026(23)00243-0.","journal-title":"Lancet Haematol"},{"issue":"5","key":"1174_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(5):393\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2405090.","journal-title":"N Engl J Med"},{"issue":"23","key":"1174_CR5","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.34987","volume":"129","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, et al. Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial. Cancer. 2023;129(23):3746\u201360. https:\/\/doi.org\/10.1002\/cncr.34987.","journal-title":"Cancer"},{"issue":"5","key":"1174_CR6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024;391(5):408\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403407.","journal-title":"N Engl J Med"},{"issue":"18","key":"1174_CR7","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1158\/1078-0432.CCR-18-0481","volume":"24","author":"JA Thompson","year":"2018","unstructured":"Thompson JA, Motzer RJ, Molina AM, Choueiri TK, Heath EI, Redman BG, et al. Phase I trials of anti-ENPP3 antibody-drug conjugates in advanced refractory renal cell carcinomas. Clin Cancer Res. 2018;24(18):4399\u2013406. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0481.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1174_CR8","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1007\/s12094-023-03261-y","volume":"25","author":"S Dominguez-Llamas","year":"2023","unstructured":"Dominguez-Llamas S, Caro-Magdaleno M, Mataix-Albert B, Aviles-Prieto J, Romero-Barranca I, Rodriguez-de-la-Rua E. Adverse events of antibody-drug conjugates on the ocular surface in cancer therapy. Clin Transl Oncol. 2023;25(11):3086\u2013100. https:\/\/doi.org\/10.1007\/s12094-023-03261-y.","journal-title":"Clin Transl Oncol"},{"key":"1174_CR9","doi-asserted-by":"publisher","first-page":"1425617","DOI":"10.3389\/fphar.2024.1425617","volume":"15","author":"K Mao","year":"2024","unstructured":"Mao K, Chen P, Sun H, Zhong S, Zheng H, Xu L. Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS). Front Pharmacol. 2024;15:1425617. https:\/\/doi.org\/10.3389\/fphar.2024.1425617.","journal-title":"Front Pharmacol"},{"key":"1174_CR10","doi-asserted-by":"crossref","unstructured":"Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, et al. (2025) Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv:In press.","DOI":"10.1182\/bloodadvances.2025016949"},{"issue":"6","key":"1174_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40262-025-01508-1","volume":"64","author":"T Papathanasiou","year":"2025","unstructured":"Papathanasiou T, Kaullen J, Polireddy K, Chen X, Ho Y, Taylor A, et al. Population pharmacokinetics for belantamab mafodotin monotherapy and combination therapies in patients with relapsed\/refractory multiple myeloma. Clin Pharmacokinet. 2025;64(6):925\u201342. https:\/\/doi.org\/10.1007\/s40262-025-01508-1.","journal-title":"Clin Pharmacokinet"},{"issue":"Supplement 1","key":"1174_CR12","doi-asserted-by":"publisher","first-page":"6730","DOI":"10.1182\/blood-2023-178026","volume":"142","author":"G Ferron-Brady","year":"2023","unstructured":"Ferron-Brady G, Taylor A, Kaullen J, Polireddy K, McKeown A, Sule N, et al. Population pharmacokinetics (PopPK) and exposure-response (E-R) analyses for belantamab mafodotin monotherapy in patients with relapsed\/refractory multiple myeloma (RRMM) enrolled in DREAMM-2 and DREAMM-3. Blood. 2023;142(Supplement 1):6730. https:\/\/doi.org\/10.1182\/blood-2023-178026.","journal-title":"Blood"},{"issue":"8","key":"1174_CR13","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/psp4.12660","volume":"10","author":"C Rathi","year":"2021","unstructured":"Rathi C, Collins J, Struemper H, Opalinska J, Jewell RC, Ferron-Brady G. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed\/refractory multiple myeloma. CPT Pharmacometrics Syst Pharmacol. 2021;10(8):851\u201363. https:\/\/doi.org\/10.1002\/psp4.12660.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"1174_CR14","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/cpt.2409","volume":"110","author":"G Ferron-Brady","year":"2021","unstructured":"Ferron-Brady G, Rathi C, Collins J, Struemper H, Opalinska J, Visser S, et al. Exposure-response analyses for therapeutic dose selection of belantamab mafodotin in patients with relapsed\/refractory multiple myeloma. Clin Pharmacol Ther. 2021;110(5):1282\u201392. https:\/\/doi.org\/10.1002\/cpt.2409.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1174_CR15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cpt.628","volume":"101","author":"Y Wang","year":"2017","unstructured":"Wang Y, Booth B, Rahman A, Kim G, Huang SM, Zineh I. Toward greater insights on pharmacokinetics and exposure-response relationships for therapeutic biologics in oncology drug development. Clin Pharmacol Ther. 2017;101(5):582\u20134. https:\/\/doi.org\/10.1002\/cpt.628.","journal-title":"Clin Pharmacol Ther"},{"issue":"14_suppl","key":"1174_CR16","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1200\/jco.2004.22.90140.6051","volume":"22","author":"H Patel","year":"2004","unstructured":"Patel H, Egorin MJ, Remick SC, Mulkerin D, Takimoto CHM, Doroshow JH, et al. Comparison of child-pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): implications for chemotherapy dosing. J Clin Oncol. 2004;22(14_suppl):6051. https:\/\/doi.org\/10.1200\/jco.2004.22.90140.6051.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1174_CR17","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","volume":"117","author":"F Gay","year":"2011","unstructured":"Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117(11):3025\u201331. https:\/\/doi.org\/10.1182\/blood-2010-09-307645.","journal-title":"Blood"},{"key":"1174_CR18","doi-asserted-by":"publisher","first-page":"S273","DOI":"10.1016\/S2152-2650(24)02315-2","volume":"24","author":"H Quach","year":"2024","unstructured":"Quach H, Dimopoulos M, Beksac M, Pour L, Delimpasi S, Vorobyev V, et al. Characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study. Clin Lymphoma Myeloma Leuk. 2024;24:S273. https:\/\/doi.org\/10.1016\/S2152-2650(24)02315-2.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"1174_CR19","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","volume":"9","author":"AV Farooq","year":"2020","unstructured":"Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020;9(4):889\u2013911. https:\/\/doi.org\/10.1007\/s40123-020-00280-8.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1174_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13045-021-01172-5","volume":"14","author":"K Marquant","year":"2021","unstructured":"Marquant K, Quinquenel A, Arndt C, Denoyer A. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report. J Hematol Oncol. 2021;14(1):159. https:\/\/doi.org\/10.1186\/s13045-021-01172-5.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1174_CR21","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.3324\/haematol.2019.235937","volume":"105","author":"R Popat","year":"2020","unstructured":"Popat R, Warcel D, O\u2019Nions J, Cowley A, Smith S, Tucker WR, et al. Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. Haematologica. 2020;105(5):e261\u20133. https:\/\/doi.org\/10.3324\/haematol.2019.235937.","journal-title":"Haematologica"},{"issue":"12","key":"1174_CR22","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117(12):1736\u201342. https:\/\/doi.org\/10.1038\/bjc.2017.367.","journal-title":"Br J Cancer"},{"issue":"6","key":"1174_CR23","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/cpt.1953","volume":"108","author":"HI Dai","year":"2020","unstructured":"Dai HI, Vugmeyster Y, Mangal N. Characterizing exposure-response relationship for therapeutic monoclonal antibodies in immuno-oncology and beyond: challenges, perspectives, and prospects. Clin Pharmacol Ther. 2020;108(6):1156\u201370. https:\/\/doi.org\/10.1002\/cpt.1953.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1174_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/psp4.13074","volume":"13","author":"MR Wiens","year":"2024","unstructured":"Wiens MR, French JL, Rogers JA. Confounded exposure metrics. CPT Pharmacometrics Syst Pharmacol. 2024;13(2):187\u201391. https:\/\/doi.org\/10.1002\/psp4.13074.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"1174_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-025-01212-0","volume":"15","author":"P Mukhopadhyay","year":"2025","unstructured":"Mukhopadhyay P, Abdullah HA, Opalinska JB, Paka P, Richards E, Weisel K, et al. The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development. Blood Cancer J. 2025;15(1):15. https:\/\/doi.org\/10.1038\/s41408-025-01212-0.","journal-title":"Blood Cancer J"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01174-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01174-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01174-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:10:21Z","timestamp":1758719421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01174-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1174"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01174-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study 207499 and the analyses reported herein were funded by GSK. Drug linker technology licensed from Seagen Inc.; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"P. Hanafin, Y.L. Ho, T. Papathanasiou, G. Fulci, N. Sule, B.E. Kremer, and G. Ferron-Brady are employees of and hold financial equities in GSK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The DREAMM-8 trial protocol and amendments were approved by the appropriate ethics body at each participating institution.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent before enrollment in DREAMM-8.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"N\/A","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"GSK makes available anonymized individual participant data and associated documents from interventional clinical studies that evaluate medicines, upon approval of proposals submitted to .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"N\/A.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization and design: P. Hanafin, Y.L. Ho, T. Papathanasiou, G. Fulci, N. Sule, B.E. Kremer, and G. Ferron-Brady; Data collection and analysis: P. Hanafin, Y.L. Ho, T. Papathanasiou, G. Fulci, N. Sule, B.E. Kremer, and G. Ferron-Brady; Writing\u2014review and editing: P. Hanafin, Y.L. Ho, T. Papathanasiou, G. Fulci, N. Sule, B.E. Kremer, and G. Ferron-Brady. The first draft of the manuscript was written by Alexus Rivas-John and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}